Comparative Pharmacology
Head-to-head clinical analysis: ATMEKSI versus AVANAFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATMEKSI versus AVANAFIL.
ATMEKSI vs AVANAFIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.
Selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing nitric oxide-mediated relaxation of smooth muscle in the corpus cavernosum, increasing cGMP levels, and promoting penile erection.
1.5 mg/kg IV every 4 weeks
100 mg orally once daily, taken 30-60 minutes before sexual activity. Maximum dosing frequency: once daily.
None Documented
None Documented
Clinical Note
moderateAvanafil + Torasemide
"Avanafil may increase the antihypertensive activities of Torasemide."
Clinical Note
moderateAvanafil + Travoprost
"Avanafil may increase the antihypertensive activities of Travoprost."
Clinical Note
moderateAvanafil + Unoprostone
"Avanafil may increase the antihypertensive activities of Unoprostone."
Clinical Note
moderateAvanafil + Hydrochlorothiazide
"Avanafil may increase the antihypertensive activities of Hydrochlorothiazide."
Terminal elimination half-life is 12 hours; renally impaired patients have prolonged half-life up to 24 hours.
Terminal elimination half-life approximately 6-8 hours. Clinical context: Supports once-daily dosing; steady-state reached within 5 days with no accumulation at FDA-approved dose.
Primarily renal (80% unchanged) and biliary/fecal (15% as metabolites).
Primarily hepatic metabolism via CYP3A4 and CYP2C9, with metabolites excreted in feces (approximately 82-90%) and urine (approximately 6-8% as unchanged drug and minor metabolites).
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor